Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

Routine prophylaxis with replacement factor VIII (FVIII) – the standard of care for severe hemophilia A – often requires frequent intravenous infusions (three or four times weekly). An FVIII molecule with an extended half‐life could reduce infusion frequency. The A‐LONG study established the safety, efficacy and prolonged pharmacokinetics of recombinant FVIII Fc fusion protein (rFVIIIFc) in previously treated adolescents and adults with severe hemophilia A.

[1]  J. Dumont,et al.  Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.

[2]  I. Nestorov,et al.  Population pharmacokinetics of recombinant factor VIII Fc fusion protein , 2015, Clinical pharmacology in drug development.

[3]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[4]  S. Jackson,et al.  An objective method for assessing adherence to prophylaxis in adults with severe haemophilia , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Windyga,et al.  Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  C. Kempton,et al.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. , 2013, Blood.

[7]  C. Kempton,et al.  Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) , 2013, Journal of thrombosis and haemostasis : JTH.

[8]  R. Gibbs,et al.  Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes , 2013, Journal of thrombosis and haemostasis : JTH.

[9]  A. Bitonti,et al.  Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein , 2013, Journal of thrombosis and haemostasis : JTH.

[10]  C. Kempton,et al.  Randomized, Controlled, Parallel-Group Trial of Routine Prophylaxis Versus On-Demand Treatment With rFVIII-FS in Adults With Severe Hemophilia A (SPINART). , 2013 .

[11]  G. Allen,et al.  Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  A. Bitonti,et al.  Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. , 2012, Blood.

[13]  J. Dumont,et al.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.

[14]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[15]  G. Spotts,et al.  Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.

[16]  P. Fogarty,et al.  Biological rationale for new drugs in the bleeding disorders pipeline. , 2011, Hematology. American Society of Hematology. Education Program.

[17]  Kathleen A. Johnson,et al.  Costs of care in hemophilia and possible implications of health care reform. , 2011, Hematology. American Society of Hematology. Education Program.

[18]  P. D. de Groot,et al.  Up-regulation of platelet activation in hemophilia A , 2011, Haematologica.

[19]  M. Morfini,et al.  Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  D. Lillicrap.  Improvements in factor concentrates , 2010, Current opinion in hematology.

[21]  S. Björkman.  Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[22]  J. O’Donnell,et al.  Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  P. Mannucci,et al.  Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  J. Astermark,et al.  Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[25]  Mats O. Karlsson,et al.  Likelihood based approaches to handling data below the quantification limit using NONMEM VI , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[26]  A. Bertomoro,et al.  A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. , 2008, Blood.

[27]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[28]  P. Lenting,et al.  Clearance mechanisms of von Willebrand factor and factor VIII , 2007, Journal of thrombosis and haemostasis : JTH.

[29]  Katsunori Yoshida,et al.  Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma , 2007, Hepatology.

[30]  R. Boulieu,et al.  A Limited Sampling Strategy for Estimating Individual Pharmacokinetic Parameters of Coagulation Factor VIII in Patients With Hemophilia A , 2007, Therapeutic drug monitoring.

[31]  H. Stass.  Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII – an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia , 2006 .

[32]  J. Maahs,et al.  Practice patterns in haemophilia A therapy – global progress towards optimal care , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[33]  J. Korth-Bradley,et al.  Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  P. Mannucci,et al.  Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods , 2005, Journal of thrombosis and haemostasis : JTH.

[35]  D. Globe,et al.  Utilization of care in haemophilia: a resource‐based method for cost analysis from the Haemophilia Utilization Group Study (HUGS) , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[36]  S. Björkman.  Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[37]  M. Manco‐Johnson,et al.  Barriers to compliance with prophylaxis therapy in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[39]  C. Denis,et al.  Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Cowan,et al.  Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. , 2000, Blood.

[41]  Chediak,et al.  Pharmacokinetics, efficacy and safety of Humate‐P® in von Willebrand disease , 1998 .

[42]  K. Mohlke,et al.  von Willebrand disease and quantitative variation in von Willebrand factor. , 1997, The Journal of laboratory and clinical medicine.

[43]  E. Berntorp,et al.  Pharmacokinetic dosing in prophylactic treatment of hemophilia A , 1993, European journal of haematology.

[44]  K. Titani,et al.  Human plasma alpha 2-macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood group antigens in subjects with corresponding ABO phenotype. , 1993, Blood.

[45]  W. Marks,et al.  The effect of ABO blood group on the diagnosis of von Willebrand disease. , 1987, Blood.

[46]  J. Wear,et al.  Experience with estramustine phosphate. , 1976, Wisconsin medical journal.